Yüklüyor......
Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C
BACKGROUND: Cost-benefit analyses are crucial to inform treatment policies, particularly when the cost of patented drugs is very high. The cost of patented drugs is the limiting factor in hepatitis C treatment. However, hepatitis C drug costs are expected to fall following patent expiration, due to...
Kaydedildi:
| Yayımlandı: | Clinicoecon Outcomes Res |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6159796/ https://ncbi.nlm.nih.gov/pubmed/30288069 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S171248 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|